An acute lymphoblastic leukemia cell-based preclinical assay revealed
functional differences of commercial L-asparaginase administered in
Colombia
Abstract
L-asparaginase (L-ASNase) is an essential component of chemotherapy
schemes due to its differential action over normal and leukemic cells.
Recently, concerns on the performance of commercial formulations
administered in developing countries have been reported. To address this
problem, we developed a cell-based protocol to compare the activity of
different L-ASNase formulations used in Colombia. We found three
statistically different groups, ranging from full to no activity on
leukemic cells using 0.05, 0.5 and 5.0 IU/mL concentrations. According
to our results, we advise a preclinical evaluation for formulations of
L-ASNase distributed in developing countries which could impact the
outcome of patients.